Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 15, 2024
TORL BioTherapeutics Secures $158 Million for Novel ADC Oncology Pipeline
Details : The financing will continue clinical development of TORL-1-23, a potentially best-in-class ADC for Claudin 6 positive tumors, through Phase 1 and pivotal Phase 2 trials.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : TORL-4-500
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 22, 2023
Lead Product(s) : TORL-4-500
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TORL-3-600
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : TORL-3-600
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The net funding will used to advance TORL-1-23, a first-in-class, clinical-stage ADC targeting Claudin 6, TORL-2-307, a clinical-stage ADC targeting Claudin 18.2 and other novel clinical and preclinical stage programs.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : TORL-2-307-MAB
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : TORL-2-307-MAB
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TORL-2-307-ADC
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 14, 2021
Lead Product(s) : TORL-2-307-ADC
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TORL-1-23
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 02, 2021
Lead Product(s) : TORL-1-23
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Research In Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable